Anderson Hoagland & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Anderson Hoagland & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.82M	Hold	15,734	–	–	0.61%	47
2026 Q1	$7.03M	Hold	15,734	–	–	0.6%	47
2025 Q4	$7.13M	Sell	15,734 -33	-0.2%	-$14.2K	0.61%	47
2025 Q3	$6.17M	Sell	15,767 -3,880	-20%	-$1.62M	0.55%	50
2025 Q2	$8.75M	Sell	19,647 -176	-0.9%	-$81.1K	0.83%	34
2025 Q1	$9.36M	Sell	19,823 -1,352	-6%	-$630K	1.11%	26
2024 Q4	$8.94M	Sell	21,175 -87	-0.4%	-$40.3K	0.92%	30
2024 Q3	$9.68M	Buy	21,262 +26	+0.1%	+$12.5K	0.99%	32
2024 Q2	$10.3M	Buy	21,236 +63	+0.3%	+$27.3K	1.08%	28
2024 Q1	$8.42M	Buy	21,173 +4,499	+27%	+$1.9M	0.94%	33
2023 Q4	$7.29M	Buy	+16,674	New	+$6.16M	0.89%	34

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

SMDAM

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.5B AUM 37.68% 1-Year Est. Return

Anderson Hoagland & Co's VRTX Position: Q2 2026 in Review

Anderson Hoagland & Co held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 15,734 shares worth $7.82M. The position accounts for 0.61% of the portfolio, ranked #47.

Anderson Hoagland & Co first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $10.3M in Q2 2024. 337 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Anderson Hoagland & Co held 15,734 shares of Vertex Pharmaceuticals worth $7.82M as of Q2 2026.
Anderson Hoagland & Co left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.61% of Anderson Hoagland & Co's portfolio in Q2 2026, its #47 holding.
Anderson Hoagland & Co first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Anderson Hoagland & Co's Vertex Pharmaceuticals position peaked at $10.3M in Q2 2024.
337 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Anderson Hoagland & Co's 13F filing for Q2 2026, filed 6 Jul 2026.